Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.38 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838439 | 0.85 | PI4KA (0.43) | ALDH1A1HPGDTSHRSLC2A1SLC2A2 | |
| SCHEMBL4928544 | 0.81 | ALDH1A1 (0.56) | ALDH1A1HPGDTSHRSLC2A1SLC2A2 | |
| SCHEMBL21138500 | 0.74 | POLB (0.39) | ALDH1A1HPGDTSHRHSD17B10NPC1 | |
| SCHEMBL5472860 | 0.73 | PI4KA (0.49) | SLC2A1SLC2A2SLC2A3LMNA | |
| SCHEMBL839210 | 0.72 | GCK (0.47) | ALDH1A1TSHRSLC2A1SLC2A2SLC2A3 | |
| SCHEMBL4146059 | 0.72 | HCAR1 (0.45) | ALDH1A1SLC2A1LMNAHTTMAPT | |
| SCHEMBL4923637 | 0.72 | ALDH1A1 (0.69) | ALDH1A1HPGDTSHRHSD17B10TP53 | |
| SCHEMBL5474281 | 0.69 | KDM4E (0.45) | ALDH1A1HPGDTSHRHSD17B10KDM4E | |
| SCHEMBL4922738 | 0.69 | ALDH1A1 (0.64) | ALDH1A1HPGDTSHRPKMKDM4E | |
| SCHEMBL5407919 | 0.68 | CNR1 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220025221-A1 | LATENTLY REACTIVE ADHESIVE FILM | TESA SE (DE) | 2022-01-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
| WO-2007080109-A1 | SUBSTITUDED BENZYLOXY-PHENYLMETHYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-07-19 | — | — | WO | disclosed |
| US-7160848-B2 | Polymers and laundry detergent compositions containing them | UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| EP-1720877-A2 | ARYL SUBSTITUTED PURINE ANALOGUES | Neurogen Corporation (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005084401-A2 | ARYL SUBSTITUTED PURINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | ALDH1A1 1918/4885HPGD 694/4885TSHR 1264/4885 |
| US-20070197559-A1 | Aryl substituted purine analogues | ADORA2A, GART, P2RX7 | ALDH1A1 569/4885HPGD 975/4885TSHR 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.